Shares of Cytokinetics, Incorporated (NASDAQ:CYTK - Get Free Report) hit a new 52-week low on Monday. The stock traded as low as $53.40 and last traded at $54.08, with a volume of 207,722 shares traded. The stock had previously closed at $56.13.
Analyst Upgrades and Downgrades
A number of equities research analysts have recently issued reports on CYTK shares. Citizens Jmp boosted their price target on shares of Cytokinetics from $105.00 to $110.00 and gave the company a "market outperform" rating in a research note on Friday, August 7th. William Blair started coverage on shares of Cytokinetics in a research report on Friday, October 16th. They set an "outperform" rating for the company. HC Wainwright reaffirmed a "buy" rating and set a $140.00 price objective on shares of Cytokinetics in a research report on Monday, October 19th. JPMorgan Chase & Co. lifted their target price on shares of Cytokinetics from $97.00 to $103.00 and gave the company an "overweight" rating in a report on Thursday, August 13th. Finally, Needham & Company LLC upped their price target on Cytokinetics from $102.00 to $112.00 and gave the stock a "buy" rating in a research note on Friday, August 7th. Nineteen research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $106.67.
Read Our Latest Stock Analysis on CYTK
Cytokinetics Stock Down 5.1%
The company's 50-day moving average price is $64.11 and its 200-day moving average price is $69.78. The firm has a market cap of $7.42 billion, a price-to-earnings ratio of -8.82 and a beta of 0.45.
Cytokinetics (NASDAQ:CYTK - Get Free Report) last announced its quarterly earnings data on Wednesday, November 4th. The biopharmaceutical company reported ($1.37) earnings per share for the quarter, beating analysts' consensus estimates of ($1.43) by $0.06. The business had revenue of $47.56 million during the quarter, compared to analyst estimates of $41.88 million. During the same quarter last year, the firm posted ($2.55) EPS. The company's revenue for the quarter was up 2356.5% on a year-over-year basis. On average, sell-side analysts predict that Cytokinetics, Incorporated will post -5.85 earnings per share for the current fiscal year.
Insider Buying and Selling
In other news, Director B. Parshall sold 5,000 shares of the company's stock in a transaction on Monday, November 9th. The stock was sold at an average price of $54.73, for a total transaction of $273,650.00. Following the sale, the director owned 5,784 shares of the company's stock, valued at approximately $316,558.32. This represents a 46.36% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Robert I. Blum sold 7,500 shares of the stock in a transaction on Monday, November 2nd. The shares were sold at an average price of $62.81, for a total value of $471,075.00. Following the completion of the sale, the chief executive officer owned 278,544 shares in the company, valued at approximately $17,495,348.64. The trade was a 2.62% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 178,426 shares of company stock worth $12,208,290 over the last ninety days. Insiders own 2.60% of the company's stock.
Hedge Funds Weigh In On Cytokinetics
A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Pictet Asset Management Holding SA increased its stake in shares of Cytokinetics by 18.4% during the third quarter. Pictet Asset Management Holding SA now owns 1,374,523 shares of the biopharmaceutical company's stock worth $90,569,000 after buying an additional 214,060 shares during the period. GW&K Investment Management LLC lifted its stake in Cytokinetics by 11.1% in the third quarter. GW&K Investment Management LLC now owns 1,017,714 shares of the biopharmaceutical company's stock worth $67,078,000 after acquiring an additional 101,607 shares during the last quarter. Fisher Asset Management LLC lifted its stake in Cytokinetics by 10.1% in the third quarter. Fisher Asset Management LLC now owns 818,832 shares of the biopharmaceutical company's stock worth $53,969,000 after acquiring an additional 75,135 shares during the last quarter. ADAR1 Capital Management LLC grew its holdings in Cytokinetics by 17.1% during the 1st quarter. ADAR1 Capital Management LLC now owns 632,556 shares of the biopharmaceutical company's stock worth $41,692,000 after acquiring an additional 92,390 shares in the last quarter. Finally, Candriam S.C.A. grew its holdings in Cytokinetics by 39.3% during the 3rd quarter. Candriam S.C.A. now owns 617,386 shares of the biopharmaceutical company's stock worth $40,841,000 after acquiring an additional 174,320 shares in the last quarter.
Cytokinetics Company Profile
(
Get Free Report)
Cytokinetics is a biopharmaceutical company focused on discovering and developing medicines that target the biology of muscle function. Its research centers on therapies for conditions involving impaired cardiac muscle performance. The company's work includes aficamten, a cardiac myosin inhibitor developed for hypertrophic cardiomyopathy, and other drug candidates designed to affect muscle contraction. Cytokinetics conducts research and clinical development through programs that may involve patients and collaborators in multiple countries.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Cytokinetics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cytokinetics wasn't on the list.
While Cytokinetics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.